I am Vice Chair and Director of the Division of Radiotherapy Physics. My clinical, research, and service activities focus on quality and safety, intensity-modulated radiation therapy, breast cancer, and quality improvement through registries. My current projects focus on advancing safety and quality using incident learning and risk analyses to guide innovation with automation. In addition, we are exploring ways to combine standardized, curated radiotherapy data with patient outcomes to support patients of today and tomorrow.
I joined Memorial Sloan Kettering Cancer Center in 2021 after nearly 30 years at the University of Michigan, where I had most recently served as Co-Director of the Physics Division in the Department of Radiation Oncology. I led the physics aspects of the Michigan Radiation Oncology Quality Consortium from its inception until my departure. I have a long history of service to the AAPM and ASTRO in scientific and educational activities. I served as past chair of the AAPM Therapy Physics Committee and as a co-author of numerous guidance documents.
I currently chair the AAPM Work Group on Task Group Review Streamlining and the AAPM Work Group on Science Council Equity Diversity and Inclusion. I am the AAPM Scientific Report Therapy Editor for Medical Physics and a member of the National Council on Radiation Protection Subcommittee 4-10 on Error Prevention in Radiation Therapy. I actively seek opportunities to support professional development at all levels from learners to leaders.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jean M. Moran discloses the following relationships and financial interests:
Equity; Fiduciary Role / Position
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.